Shares of Barclays PLC (LON:BARC – Get Free Report) have been assigned a consensus rating of “Buy” from the seven ratings firms that are currently covering the firm, Marketbeat.com reports. Seven equities research analysts have rated the stock with a buy recommendation. The average 1 year price target among brokers that have covered the stock in the last year is GBX 276 ($3.58).
Several equities research analysts have issued reports on BARC shares. Shore Capital reissued a “buy” rating on shares of Barclays in a research report on Thursday, October 24th. JPMorgan Chase & Co. reissued an “overweight” rating and set a GBX 270 ($3.50) target price on shares of Barclays in a research report on Monday, September 9th. Finally, Citigroup restated a “buy” rating on shares of Barclays in a research note on Monday, September 2nd.
Check Out Our Latest Research Report on Barclays
Insider Buying and Selling at Barclays
Barclays Trading Up 1.2 %
Shares of LON:BARC opened at GBX 243.50 ($3.16) on Tuesday. The company has a market capitalization of £35.33 billion, a price-to-earnings ratio of 936.54, a PEG ratio of 1.15 and a beta of 1.36. Barclays has a 12 month low of GBX 132.84 ($1.72) and a 12 month high of GBX 251.30 ($3.26). The firm’s 50-day moving average is GBX 229.83 and its 200 day moving average is GBX 220.49.
About Barclays
Barclays PLC provides various financial services in the United Kingdom, Europe, the Americas, Africa, the Middle East, and Asia. The company operates through Barclays UK and Barclays International division segments. It offers financial services, such as retail banking, credit cards, wholesale banking, investment banking, wealth management, and investment management services.
Featured Stories
- Five stocks we like better than Barclays
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Intel: Is Now the Time to Be Brave?
- 3 Stocks to Consider Buying in October
- Carnival or Royal Caribbean—Which Cruise Stock Has More Upside?
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer?
Receive News & Ratings for Barclays Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Barclays and related companies with MarketBeat.com's FREE daily email newsletter.